thalidomide has been researched along with Hearing Loss, Sensorineural in 1 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Hearing Loss, Sensorineural: Hearing loss resulting from damage to the COCHLEA and the sensorineural elements which lie internally beyond the oval and round windows. These elements include the AUDITORY NERVE and its connections in the BRAINSTEM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "She was also diagnosed as having a myelofibrosis with myeloid metaplasia (MMM)." | 1.33 | Endolymphatic hydrops as a cause of audio-vestibular manifestations in relapsing polychondritis. ( Horii, A; Kubo, T; Mitani, K; Mizuki, M; Murata, J; Tamura, M, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Murata, J | 1 |
| Horii, A | 1 |
| Tamura, M | 1 |
| Mitani, K | 1 |
| Mizuki, M | 1 |
| Kubo, T | 1 |
1 other study available for thalidomide and Hearing Loss, Sensorineural
| Article | Year |
|---|---|
Endolymphatic hydrops as a cause of audio-vestibular manifestations in relapsing polychondritis.
Topics: Acute Disease; Audiometry, Evoked Response; Autoimmune Diseases; C-Reactive Protein; Diagnosis, Diff | 2006 |